All Cosmos Bio-Tech Holding Corporation (TPE:4148)
Taiwan · Delayed Price · Currency is TWD 36.50
0.00 (0.00%)
Feb 11, 2026, 1:30 PM CST
TPE:4148 Income Statement
Financials in millions TWD. Fiscal year is January - December.
Millions TWD. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
Period Ending | Sep '25 Sep 30, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 |
| 2,828 | 2,459 | 2,827 | 3,702 | 2,197 | 1,643 | |
Revenue Growth (YoY) | 21.79% | -13.02% | -23.65% | 68.49% | 33.76% | -7.07% |
Cost of Revenue | 2,041 | 1,790 | 2,239 | 2,565 | 1,603 | 1,271 |
Gross Profit | 786.54 | 668.59 | 587.98 | 1,138 | 594.37 | 372.15 |
Selling, General & Admin | 516.71 | 501.14 | 396.35 | 475.57 | 377.78 | 274.52 |
Research & Development | 3.43 | 3.74 | 3.73 | 2.28 | 3.85 | 2.54 |
Operating Expenses | 523.61 | 512.71 | 398.08 | 470.58 | 321.12 | 269.44 |
Operating Income | 262.93 | 155.88 | 189.9 | 666.99 | 273.24 | 102.71 |
Interest Expense | -13.94 | -6.08 | -3.98 | -18.81 | -4.54 | -4.44 |
Interest & Investment Income | 23.71 | 35.23 | 30.42 | 11.49 | 9.43 | 18.8 |
Earnings From Equity Investments | 3.39 | 2.81 | 5.35 | 1.93 | 1.69 | -1.3 |
Currency Exchange Gain (Loss) | -9.41 | 38.38 | 39.24 | -41.87 | 21.82 | 19.08 |
Other Non Operating Income (Expenses) | 6.02 | 18.26 | -5.61 | 12.35 | 20.06 | 14.66 |
EBT Excluding Unusual Items | 272.7 | 244.48 | 255.31 | 632.08 | 321.7 | 149.52 |
Impairment of Goodwill | -0.8 | -0.8 | - | - | - | - |
Gain (Loss) on Sale of Investments | 2.07 | 2.07 | 2.74 | 1.9 | - | - |
Gain (Loss) on Sale of Assets | -2.21 | 1.2 | -0.42 | -0.03 | -0.12 | 0.15 |
Other Unusual Items | 0.1 | 5.81 | - | - | - | - |
Pretax Income | 271.86 | 252.77 | 257.63 | 633.95 | 321.59 | 149.67 |
Income Tax Expense | 92.8 | 78.28 | 68.32 | 177.93 | 84.93 | 51.5 |
Earnings From Continuing Operations | 179.06 | 174.49 | 189.31 | 456.02 | 236.65 | 98.17 |
Minority Interest in Earnings | -41.15 | -45.9 | -49.95 | -87.82 | -38.53 | -15.96 |
Net Income | 137.92 | 128.59 | 139.36 | 368.2 | 198.13 | 82.2 |
Net Income to Common | 137.92 | 128.59 | 139.36 | 368.2 | 198.13 | 82.2 |
Net Income Growth | 37.90% | -7.73% | -62.15% | 85.84% | 141.02% | 130.30% |
Shares Outstanding (Basic) | 67 | 67 | 67 | 67 | 67 | 67 |
Shares Outstanding (Diluted) | 68 | 68 | 74 | 69 | 67 | 67 |
Shares Change (YoY) | -2.80% | -8.59% | 7.16% | 2.86% | 0.14% | 0.02% |
EPS (Basic) | 2.05 | 1.91 | 2.07 | 5.48 | 2.95 | 1.22 |
EPS (Diluted) | 2.04 | 1.85 | 2.03 | 5.38 | 2.94 | 1.22 |
EPS Growth | 37.27% | -8.91% | -62.30% | 82.82% | 141.42% | 129.62% |
Free Cash Flow | 34.37 | -85.51 | 796.49 | -16.92 | -171.35 | -161.84 |
Free Cash Flow Per Share | 0.51 | -1.26 | 10.72 | -0.24 | -2.54 | -2.40 |
Dividend Per Share | 0.476 | 0.476 | 0.952 | 2.381 | 1.429 | 0.952 |
Dividend Growth | -50.00% | -50.00% | -60.00% | 66.67% | 50.00% | - |
Gross Margin | 27.82% | 27.19% | 20.80% | 30.73% | 27.05% | 22.65% |
Operating Margin | 9.30% | 6.34% | 6.72% | 18.02% | 12.44% | 6.25% |
Profit Margin | 4.88% | 5.23% | 4.93% | 9.95% | 9.02% | 5.00% |
Free Cash Flow Margin | 1.22% | -3.48% | 28.18% | -0.46% | -7.80% | -9.85% |
EBITDA | 316.51 | 199.16 | 230.19 | 709.9 | 315.03 | 145.42 |
EBITDA Margin | 11.19% | 8.10% | 8.14% | 19.17% | 14.34% | 8.85% |
D&A For EBITDA | 53.58 | 43.28 | 40.29 | 42.9 | 41.79 | 42.71 |
EBIT | 262.93 | 155.88 | 189.9 | 666.99 | 273.24 | 102.71 |
EBIT Margin | 9.30% | 6.34% | 6.72% | 18.02% | 12.44% | 6.25% |
Effective Tax Rate | 34.13% | 30.97% | 26.52% | 28.07% | 26.41% | 34.41% |
Updated Sep 30, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.